Yeji

$KRYS

Krystal Biotech, Inc.

Runway:cash-flow +
NasdaqMarket cap: —CIK 0001711279

Upcoming catalysts

1 surfaced
NDA/BLA filedDate TBD~ low confidence
$KRYSKrystal Biotech, Inc.
“Krystal Biotech, Inc. (the ”

Drug pipeline

vyjuvek
treatment of patients six months of age or older with either recessive or dominant Dystrophic Epidermolysis Bullosa
beremagene geperpavec
Dystrophic Epidermolysis Bullosa
KB803
Dystrophic Epidermolysis Bullosa
KB707
Cancer
KB301
Skin Roughness
KB105
TGM-1 Related Autosomal Recessive Congenital Ichthyosis
KB304
Wrinkles in Decolletage
KB407 (Nebulization)
Cystic Fibrosis
KB408 (Nebulization)
Alpha 1-Antitrypsin Deficiency
Open Label Topical Beremagene Geperpavec (B-VEC)
Dystrophic Epidermolysis Bullosa
Topical beremagene geperpavec
Dystrophic Epidermolysis Bullosa
KB801
Neurotrophic Keratitis

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT04917887——Recruiting2028-05-25
NCT05970497KB707Phase 2Recruiting2027-07-01
NCT06228326KB707Phase 2Recruiting2027-02-01
NCT07016750KB803Phase 3Recruiting2026-12-01
NCT06999733KB801Phase 2Recruiting2026-12-01
NCT05504837KB407 (Nebulization)Phase 1Recruiting2026-12-01
NCT06563414——Recruiting2025-12-01
NCT06049082KB408 (Nebulization)Phase 1Recruiting2025-12-01
NCT06724900KB304Phase 2Active Not Recruiting2025-07-01
NCT04540900KB301Phase 1Active Not Recruiting2024-10-16
NCT05095246KB407 (Nebulization)Phase 1Withdrawn2024-07-01
NCT05735158KB105Phase 2Unknown2024-03-01
NCT04917874Open Label Topical Beremagene Geperpavec (B-VEC)Phase 3Completed2023-07-31
NCT04047732KB105Phase 2Unknown2022-10-01
NCT04491604Topical beremagene geperpavecPhase 3Completed2021-10-29
NCT04214002——Withdrawn2020-02-24
NCT03536143Topical beremagene geperpavecPhase 2Completed2019-11-01

Recent catalysts

FDA approvalMay 19, 2023· 1114d ago
$KRYSKrystal Biotech, Inc.
vyjuvek · treatment of patients six months of age or older with either recessive or dominant Dystrophic Epidermolysis Bullosa
“On May 19, 2023, Krystal Biotech, Inc. (the ”
PDUFAMay 19, 2023· 1114d ago· unknown
$KRYSKrystal Biotech, Inc.
beremagene geperpavec · Dystrophic Epidermolysis Bullosa
“The Prescription Drug User Fee Act goal date has been extended by three months to May 19, 2023.”
PDUFAFeb 17, 2023· 1205d ago· unknown
$KRYSKrystal Biotech, Inc.
beremagene geperpavec · Dystrophic Epidermolysis Bullosa
“The application has been granted Priority Review designation and the FDA has set a Prescription Drug User Fee Act action date of February 17, 2023.”
NDA/BLA filedAug 18, 2022· 1388d ago· unknown
$KRYSKrystal Biotech, Inc.
beremagene geperpavec · Dystrophic Epidermolysis Bullosa
“On August 18, 2022, the FDA accepted the Company's BLA for B-VEC for the treatment of patients with dystrophic epidermolysis bullosa.”